Allena Pharmaceuticals Announces Postponement of Special Event

NEWTON, Mass., July 05 12, 2022 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class oral enzyme therapeutics to treat patients with metabolic disorders and rare and serious kidney disease, today announced that it has postponed its special meeting, which was scheduled for July 5, 2022, to, among other things, consider and vote on a proposed amendment to its Amended and Restated Certificate of Incorporation , as amended, to effect a reverse stock split of its issued and outstanding common shares.

The date of the adjourned special meeting and the new record date for determining Allena shareholders eligible to vote thereat will be determined in the near future and will be included in supplemental proxy materials to be filed with the SEC and distributed to shareholders promptly after the new record date.

About Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of first-in-class oral biologic therapeutics to treat patients with rare and serious metabolic and renal disorders.

Additional information and where to find it

In connection with the special meeting described above, the Company has filed a definitive proxy statement with the Securities and Exchange Commission on May 24, 2022 and in connection with the adjourned meeting, the Company will file with the Securities and Exchange Commission Supplement to Definitive Proxy Circular. This press release does not contain all of the information that should be taken into account regarding the matters to be considered at the special meeting, including the proposed reverse stock split, and is not intended to constitute the basis of an investment decision or any other decision relating to such matters.

Shareholders of the Company and other interested persons are advised to read the definitive management proxy circular and, when available, the proxy supplement and any amendments thereto, as well as any other documents filed in connection with the matters to be considered at the special meeting, including the proposed share consolidation, as these documents will contain important information about the Company and such matters. Company stockholders may also obtain free copies of these SEC filings, when available, at the SEC’s website at www.sec.gov, or by making a request to the Corporate Secretary of the Company /o Allena Pharmaceuticals, Inc., One Newton Executive Park, Suite 202, Newton, MA 02462.

Appointment of Proxy Counsel and Participants in the Solicitation

The Company has engaged Saratoga Proxy Consulting LLC (“Saratoga”) to assist us in soliciting proxies in connection with the special meeting. We expect to pay Saratoga a fee of $25,000, plus reimbursement for certain expenses related to its services.

The Company and its directors and officers may also be considered participants in the solicitation of proxies from shareholders of the Company in connection with the special meeting. A list of the names of such directors and officers and a description of their interests in the company are contained in the company’s annual report for the year ended December 31, 2021 on Form 10-K, as amended, which has been filed with the SEC. and is available free of charge on the SEC’s website at www.sec.gov. To the extent such holdings of Company securities may have changed since then, such changes have been or will be reflected in the change of ownership statements on Form 4 filed with the SEC. Additional information regarding the interests of such participants will be contained in the definitive proxy statement, supplemental proxy and any amendments thereto and any other material filed in connection with the adjourned special meeting when it becomes available.

Forward-looking statements

Certain information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the adjourned special meeting. We may, in some cases, use terms such as “predicts”, “believes”, “potential”, “continues”, “anticipates”, “estimates”, “expects”, “plans”, “has ‘intent to’, ‘may, ‘could’, ‘might’, ‘shall’, ‘should’ or other words that convey uncertainty about future events or results to identify these forward-looking statements. Our forward-looking statements are based on the current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions and uncertainties Any or all of the forward-looking statements may prove to be incorrect or be affected by inaccurate assumptions that we could do or by known and unknown risks and uncertainties as a result of various important factors, including uncertainties relating to market conditions and the completion of the offering on the terms anticipated or not at all, the satisfaction of customary closing dates relating to the recorded direct offering and various other factors. the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business generally, please see our most recent Annual Report on Form 10-K and our quarterly report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Contact with Investor Relations:
Email: [email protected]
Phone: 617-467-4577
Fax: 617-916-1871

About Jason Norton

Check Also

Low stock price triggers Nasdaq delisting warning for AlerisLife

AlerisLife (Nasdaq: ALR) needs to raise its stock price or face possible delisting from the …